Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Efficacy and Safety Study of Tunodafil Hydrochloride Tablets in Erectile Dysfunction

7 luglio 2026 aggiornato da: Yangtze River Pharmaceutical Group Co., Ltd.

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Tunodafil Hydrochloride Tablets in Patients With Erectile Dysfunction

This is a multicenter, randomized, double blind, placebo-controlled, parallel design study to evaluate the efficacy and safety of Tunodafil Hydrochloride Tablets in men with erectile dysfunction.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

780

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Cina
      • Beijing, Cina
        • Peking University Third Hospital
      • Beijing, Cina
        • Peking Union Medical College Hospital
      • Beijing, Cina
        • Peking University People's Hospital
      • Beijing, Cina
        • Peking University Shougang Hospital
      • Beijing, Cina
        • Beijing Tiantan Hospital
      • Beijing, Cina
        • Beijing Tsinghua Changgung Hospital
      • Beijing, Cina
        • Beijing Chaoyang Hospital Capital Medical University
      • Beijing, Cina
        • Xiyuan Hospital Beijing
      • Changchun, Cina
        • The First Hospital of Jilin University
      • Changchun, Cina
        • Affiliated Hospital of Changchun University of Chinese Medicine
      • Changsha, Cina
        • The Third Xiangya Hospital of Central South University
      • Chengdu, Cina
        • Chengdu University Affiliated Hospital
      • Dalian, Cina
        • The First Affiliated Hospital of Dalian Medical University
      • Fuzhou, Cina
        • The First Affiliated Hospital of Fujian Medical University
      • Guangzhou, Cina
        • Guangzhou First People's Hospital
      • Guangzhou, Cina
        • The Fifth Affiliated Hospital of Guangzhou Medical University
      • Guangzhou, Cina
        • Nanfang Hospital Southern Medical University
      • Guangzhou, Cina
        • Guangdong Provincial Hospital of Chinese Medicine
      • Hangzhou, Cina
        • Zhejiang Provincial People's Hospital
      • Hefei, Cina
        • The First Affiliated Hospital of Anhui Medical University
      • Hefei, Cina
        • The Second Affiliated Hospital of Anhui Medical University
      • Hefei, Cina
        • Hefei Second People's Hospital
      • Huai'an, Cina
        • Huaian First People's Hospital
      • Jinan, Cina
        • Shandong Provincial Hospital
      • Lanzhou, Cina
        • The First Hospital of Lanzhou University
      • Lanzhou, Cina
        • Lanzhou University Second Hospital
      • Nanchang, Cina
        • The First Affiliated Hospital of Nanchang University
      • Nanchang, Cina
        • Jiangxi Provincial People's Hospital
      • Nanchang, Cina
        • Nanchang Reproductive Hospital
      • Nanjing, Cina
        • Nanjing Drum Tower Hospital
      • Nanjing, Cina
        • Jiangsu Province Hospital of Chinese Medicine
      • Nanjing, Cina
        • Nanjing Jiangning Hospital
      • Nanning, Cina
        • Nanning Second People's Hospital
      • Shanghai, Cina
        • Shanghai Pudong Hospital
      • Shanghai, Cina
        • Shanghai Tongji Hospital
      • Shanghai, Cina
        • Longhua Hospital Shanghai
      • Shanghai, Cina
        • Xinhua Hospital Shanghai
      • Shenzhen, Cina
        • The Eighth Affiliated Hospital of Sun Yat-sen University
      • Shenzhen, Cina
        • Shenzhen Bao'an Songgang People's Hospital
      • Shijiazhuang, Cina
        • The Second Hospital of Hebei Medical University
      • Suzhou, Cina
        • The First Affiliated Hospital of Soochow University
      • Suzhou, Cina
        • Nuclear Industry General Hospital
      • Taiyuan, Cina
        • First Hospital of Shanxi Medical University
      • Tianjin, Cina
        • Tianjin Medical University General Hospital
      • Wenzhou, Cina
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan, Cina
        • Tongji Hospital Wuhan
      • Wuhu, Cina
        • Yijishan Hospital of Wannan Medical College
      • Xi'an, Cina
        • The Second Affiliated Hospital of Xi'an Jiaotong University
      • Xiamen, Cina
        • The First Affiliated Hospital of Xiamen University
      • Xuzhou, Cina
        • The Affiliated Hospital of Xuzhou Medical University
      • Zhengzhou, Cina
        • Henan Provincial People's Hospital
      • Zhengzhou, Cina
        • Zhengzhou People's Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • - Male subjects aged between 18 and 65 years (inclusive) diagnosed with Erectile Dysfunction (ED).
  • At Visit 1, subjects must have an International Index of Erectile Function-5 (IIEF-5) score ≤ 21, with a disease duration of at least 6 months.
  • Subjects must have a stable marital relationship or a stable female sexual partner for at least 3 months prior to screening and throughout the study period.
  • Subjects must agree to attempt sexual intercourse at least 4 times per visit cycle.
  • Subjects agree not to use any other ED treatments during the study, including PDE5 inhibitors, traditional Chinese medicine (including decoctions and patent medicines), or medical devices for ED treatment.
  • Subjects (and their partners) must have no plans for conception from the time of screening up to 3 months after the last dose, and must voluntarily use effective contraceptive measures.
  • Subjects must voluntarily provide written informed consent.

  • Upon completion of the run-in period, subjects must meet all of the following three conditions:

    • At least 4 sexual intercourse attempts were made during the run-in period; ② The failure rate of sexual intercourse attempts was ≥ 50% (failure defined as at least one "No" answer to the first three questions of the Sexual Encounter Profile [SEP] diary); ③ The IIEF-Erectile Function (IIEF-EF) domain score was ≥ 5 and ≤ 25.

Exclusion Criteria:

  • - Subjects with obvious congenital malformations or anatomical abnormalities of the genitalia that significantly impair penile erection.
  • Subjects with erectile dysfunction caused by other sexual dysfunction disorders (e.g., ejaculatory disorders) or uncontrolled endocrine diseases despite medication (e.g., hypogonadism, hyperthyroidism/hypothyroidism, pituitary tumors).
  • Subjects with erectile dysfunction resulting from spinal cord injury or radical prostatectomy.
  • Subjects with a history of penile prosthesis implantation.
  • Subjects with a history of sudden hearing loss or deafness.
  • Subjects who have previously failed PDE5 inhibitor therapy for erectile dysfunction.

  • Subjects with any history of the following cardiac conditions:

    • Myocardial infarction or stroke within the past 6 months;
    • Concomitant unstable angina or angina occurring during sexual intercourse;
    • New York Heart Association (NYHA) Class ≥ II heart failure within the past 6 months;
    • Concomitant uncontrolled hypertension (≥160/95 mmHg), hypotension (<90/60 mmHg), or orthostatic hypotension.
  • Subjects currently using, or unable to discontinue during the study, any formulation of nitrates or nitric oxide (NO) donors, α1-adrenergic receptor blockers (e.g., doxazosin, prazosin), strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir), or guanylate cyclase stimulators (e.g., riociguat).
  • Subjects with a history of anti-androgen therapy, or androgen replacement therapy initiated less than 3 months prior to screening without a stable maintenance regimen.
  • Subjects with poorly controlled diabetes mellitus, defined as fasting blood glucose >1.5 times the upper limit of normal (ULN), or those with diabetic complications (diabetic nephropathy, peripheral neuropathy).
  • Subjects with severe hepatic or renal impairment, defined as AST and/or ALT >2 × ULN; or creatinine clearance (CrCl) <30.0 mL/min.
  • Subjects with a history of severe chronic or acute hepatitis.
  • Subjects who have used vacuum constriction devices (VCD), intracavernosal injections (ICI), or other ED therapies and are unable to discontinue these treatments during the study.
  • Subjects with known color vision abnormalities, retinitis pigmentosa, macular degeneration, non-arteritic anterior ischemic optic neuropathy (NAION), or other fundus disease histories.
  • Subjects with severe central nervous system damage within the past 6 months (cerebrovascular diseases such as cerebral hemorrhage or ischemia, inflammatory brain diseases such as encephalitis or meningitis, craniocerebral trauma, or spinal cord injury), or peripheral nervous system injury or lesions.
  • Subjects with a history of high-risk arrhythmias, or ECG-confirmed arrhythmias, or those with clinically significant abnormal ECG findings at screening as judged by the Investigator.
  • Subjects with a history of malignant tumors within the past 3 years (excluding basal cell carcinoma, squamous cell carcinoma of the skin, or other non-invasive lesions deemed cured by the Investigator with minimal recurrence risk).
  • Subjects with a known hypersensitivity to the investigational product or drugs of the same class.
  • Subjects with a history of psychiatric disorders.
  • Subjects with a history of substance abuse, drug addiction, or alcoholism (characterized by impaired tolerance, withdrawal, or control over drinking behavior) within the past year.
  • Subjects who participated in another clinical trial within 1 month prior to screening.
  • Subjects whose female partners are <18 years of age, or whose partners are known to be pregnant at screening, unwilling to use appropriate contraception during the study, or are breastfeeding.
  • Subjects whose partners have gynecological conditions that may affect sexual activity or other medical conditions limiting their participation in the clinical trial.
  • Subjects deemed unsuitable for inclusion by the Investigator for any other reason.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Gruppo placebo
Droga: Placebo
All enrolled participants will receive a 12-week treatment regimen. Researchers shall instruct participants on proper medication administration, requiring the drug to be taken approximately 1 hour prior to sexual activity and followed by sexual stimulation. Each participant must take the medication at least four times per visit cycle, with no more than one dose administered within a 24-hour period.
Sperimentale: Tunodafil Hydrochloride Tablets 50mg group
Droga: Tunodafil Hydrochloride Tablets 50mg
All enrolled participants will receive a 12-week treatment regimen. Researchers shall instruct participants on proper medication administration, requiring the drug to be taken approximately 1 hour prior to sexual activity and followed by sexual stimulation. Each participant must take the medication at least four times per visit cycle, with no more than one dose administered within a 24-hour period.
Sperimentale: Tunodafil Hydrochloride Tablets 100mg group
Droga: Tunodafil Hydrochloride Tablets 100mg
All enrolled participants will receive a 12-week treatment regimen. Researchers shall instruct participants on proper medication administration, requiring the drug to be taken approximately 1 hour prior to sexual activity and followed by sexual stimulation. Each participant must take the medication at least four times per visit cycle, with no more than one dose administered within a 24-hour period.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Variazione rispetto al basale nella domanda 2 del diario del profilo dell'incontro sessuale del paziente (SEP) alla settimana 12 nella percentuale di risposte affermative
Lasso di tempo: basale e 12 settimane
È stata valutata la variazione media rispetto al basale nella percentuale di risposte Sì alla domanda 2 del diario SEP. "Sei riuscito a inserire il tuo pene nella vagina del tuo partner quando stai cercando di fare sesso?" I dati sono presentati come percentuale media di risposte sì per partecipante.
basale e 12 settimane
Variazione rispetto al basale nella domanda 3 del diario SEP (Patient Sexual Encounter Profile) alla settimana 12 nella percentuale di risposte affermative
Lasso di tempo: basale e 12 settimane
È stata valutata la variazione media rispetto al basale nella percentuale di risposte Sì alla domanda 3 del diario SEP. "La tua erezione è durata abbastanza a lungo da consentirti di avere rapporti sessuali di successo?" I dati sono presentati come percentuale media di risposte sì per partecipante.
basale e 12 settimane
Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) at Week 12
Lasso di tempo: baseline and 12 weeks
The primary efficacy variable was the change in the EF domain scores of the IIEF questionnaire from baseline, calculated by comparing total scores from questions 1-5 and 15 from the IIEF questionnaire
baseline and 12 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) ≥26 at Week 12
Lasso di tempo: baseline and 12 weeks
Assessed was the changes in the number of subjects whose IIEF domain score at the 12th week visit was ≥26.
baseline and 12 weeks
Change From Baseline in the International Index of Erectile Function - Orgasmic Functions Domain (IIEF-OF) at Week 12
Lasso di tempo: baseline and 12 weeks
The change in the OF domain scores of the IIEF questionnaire from baseline, calculated by comparing total scores from questions 9 and 10 from the IIEF questionnaire.
baseline and 12 weeks
Change From Baseline in the International Index of Erectile Function - Sexual Desire Domain (IIEF-SD) at Week 12
Lasso di tempo: baseline and 12 weeks
The change in the SD domain scores of the IIEF questionnaire from baseline, calculated by comparing total scores from questions 11 and 12 from the IIEF questionnaire.
baseline and 12 weeks
Change From Baseline in the International Index of Erectile Function - Intercourse Satisfaction Domain (IIEF-IS) at Week 12
Lasso di tempo: baseline and 12 weeks
The change in the IS domain scores of the IIEF questionnaire from baseline, calculated by comparing total scores from questions 6-8 from the IIEF questionnaire.
baseline and 12 weeks
Change From Baseline in the International Index of Erectile Function - Overall Satisfaction Domain (IIEF-OS) at Week 12
Lasso di tempo: baseline and 12 weeks
The change in the OS domain scores of the IIEF questionnaire from baseline, calculated by comparing total scores from questions 13 and 14 from the IIEF questionnaire.
baseline and 12 weeks
Proportion of patients answering "Yes" on the Global Assessment Questionnaire (GAQ). Over the past 4 weeks during treatment, has there been an improvement in erectile function following medication use?
Lasso di tempo: 12 weeks
Proportion of patients answering "Yes" to the Global Assessment Questionnaire (GAQ) question ("Over the past 4 weeks during treatment, has there been an improvement in erectile function following medication use?") at Week 12.
12 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Yangtze River Pharmaceutical Group Co., Ltd.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 aprile 2021

Completamento primario (Effettivo)

23 novembre 2021

Completamento dello studio (Effettivo)

25 gennaio 2022

Date di iscrizione allo studio

Primo inviato

24 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

7 luglio 2026

Primo Inserito (Effettivo)

9 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

9 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

7 luglio 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • YZJ200083-III-2028

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Sweden

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

3
Sottoscrivi